Abstract
Serotonin in the brain, and perhaps elsewhere, is involved in mechanisms that affect macronutrient selection, generate feelings of satiety, and, if malfunctioning, predispose to obesity. Drugs which increase the quantities of serotonin present within synapses can cause weight reduction. Such drugs presently include those that release the neurotransmitter by a direct action on nerve terminals (e.g., dexfenfluramine’s metabolite dexnorfenfluramine) or by activating serotoninergic neurons (e.g., nicotine); by activating post-synaptic serotonin receptors (e.g., dexnorfenfluramine); or by prolonging serotonin’s existence within synapses by blocking its reuptake (e.g., dexfenfluramine; fluoxetine, sertraline; paroxetine). Additional ways are known by which intrasynaptic serotonin levels can be augmented (e.g. increasing its synthesis with tryptophan; inhibiting its destruction by monoamine oxidase), and it can be anticipated that drugs acting at these loci will also become candidates for treating obesity.
Serotoninergic drugs act in at least three ways to facilitate weight loss: They accelerate the onset of satiety (Blundell, 1986), and enhance basal metabolic rate by about 100 calories per day (Fernstrom, 1989). They also inhibit the “carbohydrate craving” manifested by many people who are overweight or are becoming so (c.f., Wurtman and Wurtman, 1989). There is reason to believe that this inappropriate eating behavior actually constitutes a “serotonin hunger” by the brain, perhaps related to the number or activity of raphe neurons, in which case giving the serotoninergic drug might constitute a specific therapy for the etiologic process causing the obesity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Benwell M.E., Balfour D.J. and Anderson J.M., 1988, Evidence that tobacco smoking increases the density of (-)-[3H] nicotine binding sites in human brain, J. Neurochem.50: 1243.
Blundell J.E., 1986, Serotonin manipulations and the structure of feeding behavior, Appetite. (suppl): 39–56.
Brzezinski A. A, Wurtman J.J., Wurtman R.J., Gleason R., Nader T., and Laferrere B., 1990, d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual syndrome, Obstet. Gynecol. 76:296.
Fernstrom J.D. and Wurtman R.J.,. 1971 a, Brain serotonin content: Physiological dependence on plasma tryptophan levels, Science 173:149.
Fernstrom J.D. and Wurtman R.J., 1971 b, Brain serotonin content: Increase following ingestion of carbohydrate diet, Science174: 1023.
Fernstrom J.D., Wurtman R.J., Hammarstrom-Wiklund B., Rand W.M., Munro H.N. and Davidson C.S., 1979, Diurnal variations in plasma concentrations of tryptophan, tyrosine, and other neutral amino acids: Effect of dietary protein intake, Am. J. Clin. Nutr.32: 1912.
Fernstrom M.H., 1989, Depression, antidepressants, and body weight, Ann. N. Y. Acad. Sci.575: 31.
Fuller R.W., Snoddy H.D. and Robertson D.W., 1988, Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus release, Pharmacol. Biochem. Behav.30: 715.
Gardier A. and Wurtman R.J., 1991, Persistent blockade of potassium-evoked serotonin release from rat frontocortical terminals after fluoxetine administration, Brain Res. 540: 325.
Gardier A., Kaakkola S., Erfurth A. and Wurtman R.J., 1992, Effects of methiothepin on changes in brain serotonin release induced by repeated administration of high doses of anorectic drugs, Brain Jtes. 588 (1): 67.
Guy-Grand G., Apfelbaum M., Crepaldi G., leFebvre P., Greis A. and Turner P., 1989, International trial of long-term dexfenfluramine in obesity. Lancet2: 1142.
Kalia M., 1991, Reversible, short-lasting, and dose-dependent effect of (+)-fenfluramine on neocortical serotonergic axons, Brain Res. 548: 111.
Kalucy R.J., 1980, Drug-induced weight gain, Drugs19: 268.
Kim W., Kelay J.,Judd J., Marshall M.W., Metz W. and Prather E.S., 1987, Evaluation of long-term dietary intakes of adults consuming self-selected diets, Am. J. Clin. Nutr.40: 1327.
Laferrere B. and Wurtman R.J., 1989, Effect of d-fenfluramine on serotonin release in brains of anesthetized rats, Brain Res. 504: 258.
Leibowitz S.F., Weiss G.F. and Shor-Posner G., 1988, Hypothalamic serotonin: Pharmacological, biochemical and behavioral analyses of its feeding-suppressive action, Clin. Neuropharmacol.11. S51.
Lieberman H.R., Caballero B. and Finer N., 1986, The composition of lunch determines afternoon plasma tryptophan ratios in humans, J. Neural Transm.65: 211.
Moses P.L. and Wurtman R.J., 1984, The ability of certain anorexic drugs to suppress food consumption depends on the nutrient composition of the test diet, Life Sci. 35: 1297.
McCue H., Jr., 1981, The 1979 build and blood pressure study, in: “Medical Aspects of Mortality Statistics”, H. Bostrom, N. Ljungstedt, eds., Almquist and Wiksell International, Stockholm.
Molliver D.C. and Molliver M.E., 1990, Anatomic evidence for a neurotoxic effect of (+)- fenfluramine upon serotoninergic projections in the rat, Brain Res. 551: 165.
Pardridge W. and Flere G., 1990, Transport of tryptophan into brain from the circulating, albumin-bound pool in rats and in rabbits, J. Neurochem.54: 971.
Pi-Sunyer F., 1991, Health implications of obesity, Am. J. Clin. Nutr. 53: 1595S.
Ribeiro E., Bettiker R., Bogdanov M. and Wurtman R.J., 1993, Effects of systemic nicotine on serotonin release in rat brain, Brain Res. 621: 311.
Rosenthal N.E., Sack D.A.,Gillin J.C, Lewey A.J., Goodwin F.K., Davenport Y., Mueller P.S., Newsome D.A., and Wehr T.A., 1984, Seasonal Affective Disorder: A description of the syndrome and preliminary findings with light therapy, Arch. Gen. Psychiatry41. 72.
Rosenthal N., Genhart M., Caballero B., Jacobsen F.M., Skwerer R.G., Coursey R.D., Rogers S., and Spring B.J., 1989, Psychobiological effects of carbohydrate- and protein-rich meals in patients with Seasonal Affective Disorder and normal controls, Biol. Psychiatry.25: 1029.
Schaechter J.D. and Wurtman R.J., 1990, Serotonin release varies with brain tryptophan levels, Brain Res. 532: 203.
Schuster C.R., Lewis M. and Seiden L.S., 1986, Fenfluramine neurotoxicity, Psychopharmacol. Bull.22: 148.
Spring B., Wurtman J., Gleason R. and Kessler K., 1991, Weight gain and withdrawal symptoms after smoking cessation: A preventive intervention using d-fenfluramine, Health Psychol. 10: 216.
Toornvliet A.C., Pijl H., Hopman E., Pietero M. and Meinders A.E., 1994, The identification of obese patients sensitive to a serotoninergic drug, Abstract Presented at the 7th International Congress on Obesity, Toronto, Canada, August 20 - 25.
Trouvin J.H,. Gardier A.M, Chanut E., Pages N. and Jacquot C., 1993, Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat, Life Sci. 52: 187.
Wack J. and Rodin J., 1982, Smoking and its effect on body weight and the systems of caloric regulation, Am. J. Clin. Nutr.35: 366.
Wurtman J. J., Wurtman R.J., Reynolds S., Tsay R., and Chew B., 1987, d-Fenfluramine suppresses snack intake among carbohydrate cravers but not among non carbohydrate cravers, Int. J. of Eating Disord. 6:687.
Wurtman R.J. and Wurtman J.J., 1989, Carbohydrates and depression, Sci. Am. January: 68–75.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Plenum Press, New York
About this chapter
Cite this chapter
Wurtman, R.J., Wurtman, J.J. (1996). Brain Serotonin, Carbohydrate-Craving, Obesity and Depression. In: Filippini, G.A., Costa, C.V.L., Bertazzo, A. (eds) Recent Advances in Tryptophan Research. Advances in Experimental Medicine and Biology, vol 398. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0381-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0381-7_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8026-9
Online ISBN: 978-1-4613-0381-7
eBook Packages: Springer Book Archive